Email this article PREVALENCE OF MUTATIONS RESPONSIBLE FOR RESISTANCE TO ANTIRETROVIRAL PREPARATIONSAMONG HIV-1 VARIANTS CIRCULATING IN NOVOSIBIRSK REGION
- Authors: Gashnikova NM1, Bogachev VV1, Baryshev PB1, Meshcheryakova Y.V1, Savochkina EN1, Chernousova NY.1, Gashnikova NM2, Bogachev VV2, Baryshev PB2, Mescheryakova Y.V3, Savochkina EN3, Chernousova NY.3
-
Affiliations:
- State Scientific Centre of Virology and Biotechnology Vector
- Novosibirsk Regional Centre of Prophylaxis andControl of AIDS and Infectious Diseases, Koltsovo, Novosibirsk region, Russia
- Issue: Vol 89, No 6 (2012)
- Pages: 56-60
- Section: Articles
- Submitted: 09.06.2023
- Published: 15.12.2012
- URL: https://microbiol.crie.ru/jour/article/view/13722
- ID: 13722
Cite item
Full Text
Abstract
genome emerging in response to antiretroviral therapy isolated from HIV-infected individuals of Novosibirsk
region in 2010, 2011. Materials and methods. Detection of mutations in HIV-1 genome responsible for the
resistance to antiretroviral preparations (ARVP) was carried out by determination of pol gene nucleotide
sequence and subsequent analysis of the data obtained by program HIVdb: Genotypic Resistance Interpretation
Algorithm. Results. HIV-1 resistance mutations to antiretroviral preparations were detected in 23.6% of the
total number of the studied samples. The most prevalent mutations are those conditioning resistance to
nucleoside and non-nucleoside reverse transcriptase inhibitors (M184V, Y181C and K103N). In studies of
HIV-1 isolated from 4 patients who had not received antiretroviral therapy (ARVT) transmission of HIV-1
resistant to various groups of preparations was detected. Conclusion. The detected facts of ARVP resistant
HIV-1 circulation among patients who had not received ARVT and the data obtained on the mutations
emerging in response to therapy underline the relevance of administration of HIV-1 resistance profile study
during both decrease of ARVT effectiveness and primary administration of therapy to HIV infected patients.
About the authors
N M Gashnikova
V V Bogachev
P B Baryshev
Yu V Meshcheryakova
E N Savochkina
N Ya Chernousova
N M Gashnikova
State Scientific Centre of Virology and Biotechnology VectorState Scientific Centre of Virology and Biotechnology Vector
V V Bogachev
State Scientific Centre of Virology and Biotechnology VectorState Scientific Centre of Virology and Biotechnology Vector
P B Baryshev
State Scientific Centre of Virology and Biotechnology VectorState Scientific Centre of Virology and Biotechnology Vector
Yu V Mescheryakova
Novosibirsk Regional Centre of Prophylaxis andControl of AIDS and Infectious Diseases, Koltsovo, Novosibirsk region, RussiaNovosibirsk Regional Centre of Prophylaxis andControl of AIDS and Infectious Diseases, Koltsovo, Novosibirsk region, Russia
E N Savochkina
Novosibirsk Regional Centre of Prophylaxis andControl of AIDS and Infectious Diseases, Koltsovo, Novosibirsk region, RussiaNovosibirsk Regional Centre of Prophylaxis andControl of AIDS and Infectious Diseases, Koltsovo, Novosibirsk region, Russia
N Ya Chernousova
Novosibirsk Regional Centre of Prophylaxis andControl of AIDS and Infectious Diseases, Koltsovo, Novosibirsk region, RussiaNovosibirsk Regional Centre of Prophylaxis andControl of AIDS and Infectious Diseases, Koltsovo, Novosibirsk region, Russia
References
- Круглова А.И., Шипулин Г.А., Богословская Е.В., Буравцова Е. В. Методические рекомен- дации "Определение чувствительности вируса иммунодефицита человека к лекарственным препаратам". № 5956-РХ от 06.08.2007.
- Coffin J.M. HIV population dynamics in vivo: implications for genetic variation: pathogenesis, and therapy. Science. 1995, 267: 483-489.
- Hanna G.J., Johnson V.A., Kuritzkes D.R. et al. Patterns of resistance mutations selected by treatment HIV-1 infection with zidovudine, didanosine and nevirapine. J. Infect. Dis. 2000, 181: 904-911.
- http://hivdb6.stanford.edu.
- Sluis-Cremer N., Arion D., Parniak M.A. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs). Cell .Mol. Life Sci. 2000, 57: 1408-1422.
- Wu T.D., Schiffer C.A., Gonzales M.J. et. al. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J. Virol. 2003, 77: 4836-4847.
Supplementary files
